Standard: this guide onlyAll-Access Lifetime: all 45 guides + downloadsEducational content only
IGF-1 LR3 Guide: Available Now
Educational use only — not medical advice. This guide summarizes information reported in published research and community practice for educational purposes. It is not medical advice and not a recommendation to use any compound. Any doses, schedules, or combinations shown are examples of what has been reported, not instructions for you. Many peptides described here are research compounds that are not FDA-approved for the uses discussed and may be investigational or restricted. Effects, risks, and legal status vary; individual needs and results vary. Consult a qualified, licensed healthcare professional before making any decision. Do not use this content to diagnose, treat, or dose yourself.
IGF-1 LR3 at a glance
What it is
A synthetic 83-amino-acid analog of IGF-1 with an Arg substitution at position 3 and a 13-amino-acid N-terminal extension
Researched for
IGF-1 receptor activation, cell proliferation and protein synthesis in preclinical/laboratory models
Commonly reported range
~20-100 mcg per day (community-reported research protocols; no validated human dose exists)
Route reported
Subcutaneous injection (community-reported)
Reported frequency
Once daily, owing to its long half-life
Reported cycle
~4-6 weeks in community protocols
Plasma half-life
~20-30 hours (vs. ~10-16 minutes for native IGF-1)
Regulatory status
Not FDA-approved; sold as a research chemical; WADA-prohibited (S2) at all times
Reported ranges from research/community — examples, not recommendations.
What it is / mechanism
IGF-1 LR3 (Long R3 IGF-1) is a recombinant analog of insulin-like growth factor-1 in which an arginine replaces the glutamic acid at position 3 and a 13-amino-acid peptide is added to the N-terminus. These modifications sharply reduce its affinity for IGF binding proteins (IGFBPs), which normally sequester native IGF-1 and limit its availability. As a result, more of the molecule remains free to bind the IGF-1 receptor, and its reported half-life extends to roughly 20-30 hours compared with minutes for native IGF-1. Upon binding the IGF-1R tyrosine kinase receptor, it is reported to activate the PI3K/Akt/mTOR pathway (associated with protein synthesis) and the MAPK/ERK pathway (associated with cell proliferation). This description reflects reported and preclinical mechanisms, not confirmed clinical effects in humans.
Researched effects
In laboratory and animal research, IGF-1 LR3 has been studied for its effects on cell proliferation, protein synthesis signaling, and myocyte growth models. Community discussion frequently references muscle growth, recovery, and nutrient partitioning, but these are anecdotal reports rather than validated outcomes. No formal human clinical trial has evaluated IGF-1 LR3 for any therapeutic or performance endpoint. These are research findings and community-reported observations, not guaranteed outcomes.
Evidence & regulatory status
Evidence: Preclinical and in-vitro studies describe IGF-1R activation and downstream PI3K/Akt/mTOR and MAPK/ERK signaling; there are no completed human clinical trials establishing efficacy or a safe dose.
Regulatory: IGF-1 LR3 is not approved by the FDA for human use and is sold as a research chemical; it is prohibited by WADA at all times under Section S2 (peptide hormones, growth factors, and mimetics).
Research use: Any handling described here is for laboratory research context only and is not a recommendation for human administration.
Dosage — reported ranges (overview)
The figures below are examples of what is reported in community research protocols, not a recommendation. Community-reported protocols commonly cluster between roughly 20 and 100 mcg per day, given as a single daily injection because of the compound's long half-life, over cycles of about 4-6 weeks. Conservative examples start near 20-40 mcg, intermediate examples near 50-80 mcg, and higher examples near 100 mcg. Importantly, no human clinical trial has validated any dosing range for IGF-1 LR3, so these figures carry no assurance of safety or effect.
The full step-by-step protocol examples, titration, and printable protocol sheet are planned for a future paid Protocol Playbook module.
Reconstitution — bac-water math
IGF-1 LR3 is dosed in micrograms (mcg), so reconstitution is a concentration-math exercise, not a personal dose. When you add W mL of bacteriostatic water to a vial containing V mg of peptide, the concentration is (V x 1000) / W mcg per mL. To find how many units to draw on a U-100 insulin syringe (where 100 units = 1 mL), use: units = dose (mcg) / concentration (mcg/mL) x 100. Worked example: a 1 mg vial reconstituted with 1 mL of water gives 1000 mcg/mL; a 40 mcg example draw would be 40 / 1000 x 100 = 4 units on a U-100 syringe. Adjust the water volume to make the units easier to measure accurately.
Bac water added
Concentration
20 mcg example
50 mcg example
1 mL
1000 mcg/mL
2 units
5 units
2 mL
500 mcg/mL
4 units
10 units
3 mL
333 mcg/mL
6 units
15 units
This is concentration math, not a dose recommendation.
Pre-fills example values. Every field remains editable.
The amount printed on the vial or listed on a product page.
mL
Liquid volume used for the concentration calculation.
The mass amount to convert into liquid volume for this math example.
4. Insulin syringe size
Your result
Syringe-unit reading
10 units
= 0.1 mL · 250 mcg target amount
Concentration
2.5mg/mL
Per insulin unit
25mcg
Portions per vial
20
Volume
0.1mL
This calculator is an educational tool for laboratory and research math only. The peptides referenced are research compounds not intended for human or veterinary use, and example values are not medical advice or personal-use instructions. Follow applicable research protocols and regulations.
How the calculator works
Concentration
peptide ÷ liquid
Total peptide divided by liquid volume gives the concentration per mL.
Volume
target ÷ concentration
The target mass divided by concentration gives the liquid volume.
Syringe units
volume × 100
For insulin units, 100 units equals 1 mL, so mL is multiplied by 100.
Worked example: A 5 mg vial plus 2 mL liquid creates a 2.5 mg/mL concentration. A 250 mcg target amount equals 0.1 mL, or 10 insulin units. The vial contains 20 such portions.
Frequently asked questions
How much bacteriostatic water should I enter?+
There is no single calculator-default amount. The liquid volume controls concentration: more liquid creates a less concentrated solution and a larger volume reading for the same target amount; less liquid creates a more concentrated solution and a smaller volume reading.
How do insulin syringe units relate to mL?+
For this math tool, 100 insulin units equals 1 mL, and 1 unit equals 0.01 mL. The 0.3 mL, 0.5 mL, and 1.0 mL options change capacity, not the unit-to-mL relationship.
What is the difference between mg, mcg, and units?+
Milligrams and micrograms measure peptide mass: 1 mg = 1,000 mcg. Syringe units measure liquid volume. Reconstitution math connects mass and volume by using concentration.
Does changing the liquid volume change the total peptide in the vial?+
No. The total peptide amount entered for the vial remains fixed. Changing the liquid volume only changes concentration and the resulting volume shown by the calculator.
Injection / administration basics
In community-reported research protocols, IGF-1 LR3 is described as reconstituted with bacteriostatic water and administered subcutaneously using a U-100 insulin syringe, typically once daily due to the long half-life. General handling notes reported include swabbing the vial stopper with alcohol, adding water slowly against the vial wall rather than directly onto the powder, and gently swirling rather than shaking. This is a description of reported laboratory handling, not medical guidance or a recommendation for human use.
Half-life & frequency rationale
The N-terminal extension and position-3 arginine substitution reduce IGFBP binding and extend the reported plasma half-life to approximately 20-30 hours, in contrast to native IGF-1's circulating half-life of roughly 10-16 minutes. This extended duration is the reason community protocols describe once-daily administration.
Side effects, safety & contraindications
Because there are no completed human clinical trials, the human safety profile of IGF-1 LR3 is not established and reported side effects are largely anecdotal or extrapolated from IGF-1 biology. Commonly discussed concerns include hypoglycemia (from insulin-like signaling), localized injection-site reactions, fluid retention, and joint discomfort. There are theoretical concerns, based on IGF-1's role in cell proliferation, about promoting growth of existing abnormal tissue; these are mechanistic concerns, not established clinical findings. Human data are limited, and this information is educational, not medical advice.
Stacking — overview
In community discussion, IGF-1 LR3 is frequently described alongside growth-hormone secretagogues and repair-oriented peptides. These are examples of commonly reported pairings for context only, not recommendations, and none are clinically validated combinations.
GH secretagogue pairing
IGF-1 LR3 + CJC-1295 + Ipamorelin
Recovery-oriented pairing
IGF-1 LR3 + BPC-157 + TB-500
Local growth-factor pairing
IGF-1 LR3 + MGF
Muscle-focused pairing
IGF-1 LR3 + Follistatin
Storage & handling
Lyophilized (powder): reported as stored refrigerated (2-8°C) and protected from light; may be kept frozen for longer-term storage in research settings.
Reconstituted (in solution): reported as refrigerated at 2-8°C and used within several weeks, kept away from light and heat.
References
This guide summarizes publicly reported research summaries, analytical detection literature (e.g., Mongongu et al., 2020), and anti-doping resources from WADA and USADA; it is educational and does not constitute medical advice.
Related peptide guides
Continue exploring related educational guide topics in the Medibact library.
Quick answers about guide scope, access, and educational use context.
Is IGF-1 LR3 approved by the FDA?
No. IGF-1 LR3 is not approved by the FDA for human use or supplementation and is sold as a research chemical for laboratory use only.
Why does IGF-1 LR3 last so much longer than natural IGF-1?
Its structural modifications (a position-3 arginine substitution and a 13-amino-acid N-terminal extension) reduce binding to IGF binding proteins, which extends its reported half-life to roughly 20-30 hours versus minutes for native IGF-1.
Is IGF-1 LR3 banned in sports?
Yes. WADA prohibits IGF-1 LR3 at all times, in and out of competition, under Section S2 of the Prohibited List, and validated detection assays for it have been published.
How is it typically measured for research?
Because it is dosed in micrograms, researchers calculate concentration as (mg x 1000) / mL of water, then draw units on a U-100 syringe. This is concentration math, not a personal dose.
Is there human clinical evidence for its reported benefits?
No formal human clinical trial has evaluated IGF-1 LR3 for any therapeutic or performance endpoint; reported effects come from preclinical models and anecdotal community accounts.
Compliance and trust notes
Educational content only; no personalized health or outcome claims.
No personalized use recommendation outputs.
Use this material for general learning and research-context literacy.
Educational use only — not medical advice. This guide summarizes information reported in published research and community practice for educational purposes. It is not medical advice and not a recommendation to use any compound. Any doses, schedules, or combinations shown are examples of what has been reported, not instructions for you. Many peptides described here are research compounds that are not FDA-approved for the uses discussed and may be investigational or restricted. Effects, risks, and legal status vary; individual needs and results vary. Consult a qualified, licensed healthcare professional before making any decision. Do not use this content to diagnose, treat, or dose yourself.
